Canaccord Genuity Keeps Merit Medical at Buy, Raises Target to $121
Canaccord Genuity kept its Buy rating on Merit Medical shares and lifted its price target to $121 from $94, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, analysts at Canaccord Genuity kept their Buy rating on Merit Medical (MMSI) shares. At the same time, they raised the stock's price target to $121 per share from the previous $94. The ratings update is also listed by Benzinga, which compiles analyst actions.
why it matters
Rating changes for a single company usually matter to its own shareholders and rarely move the broader market. For investors following medical device stocks, it is a signal of how specialist analysts currently view the company.
tags
instruments
sources
- Merit Medical Is Maintained at Buy by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:46 UTC
- Perrigo Is Maintained at Buy by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:55 UTC
- Nature's Sunshine Is Maintained at Buy by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:54 UTC
- Enhanced Group Is Maintained at Buy by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗